Mesa Laboratories stock plummeted 19.5% on May 27, 2026, after reporting Q4 fiscal 2026 results. While the company beat expectations on adjusted operating income per share ($3.30 vs. $1.54 estimate), sales of $63.72 million fell short of Wall Street expectations by approximately $1.48 million. CEO Siddhartha Kadia is conducting an internal review and will provide full-year guidance with the Q2 report.

Mesa Laboratories announced a quarterly dividend of $0.16 per share, payable on September 15, 2025, to shareholders of record as of August 29, 2025.

Mesa Laboratories, Inc. (MLAB) announced a regular quarterly dividend of $0.16 per share, payable on June 16, 2025. The company is a global leader in life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries.

Mesa Laboratories, Inc. reported its second quarter fiscal year 2025 results, with revenues increasing 8.8% year-over-year. The company's Biopharmaceutical Development and Calibration Solutions divisions saw strong growth, while the Clinical Genomics division faced headwinds in China and North America.

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock, payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.

LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q24”) and fiscal year (“FY24”) ended March 31, 2024 (amounts in thousands).

LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as previously communicated. The earnings announcement has been delayed as we work to finalize our year end audit which is focused on finalizing the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions and the purchase accounting associated with the acquisition of GKE.

LAKEWOOD, Colo., May 22, 2024 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 31, 2024. Mesa’s Form 10-K will be filed the same day. The earnings announcement has been delayed as we finalize the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions.

DarioHealth (DRIO) delivered earnings and revenue surprises of 66.10% and 3.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) delivered earnings and revenue surprises of 18.18% and 1.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

SM and MLAB made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 8, 2023.

LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024.